Month 60 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion

To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion. Long-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 month...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of ophthalmology Vol. 240; pp. 330 - 341
Main Authors:	Scott, Ingrid U., VanVeldhuisen, Paul C., Oden, Neal L., Ip, Michael S., Blodi, Barbara A.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.08.2022 Elsevier Limited
Subjects:	Angiogenesis Inhibitors Bevacizumab - therapeutic use Diabetes Diabetic retinopathy Edema FDA approval Humans Intravitreal Injections Lasers Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Medical records Monoclonal antibodies Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins Retinal Vein Occlusion - complications Retinal Vein Occlusion - diagnosis Retinal Vein Occlusion - drug therapy Tomography, Optical Coherence Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors
ISSN:	0002-9394, 1879-1891, 1879-1891
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion. Long-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. Main outcomes were visual acuity letter score (VALS) and central subfield thickness (CST) on optical coherence tomography. Seventy-five percent (248/330) of eligible participants completed at least 1 visit between months 24 and 60, and 45% completed the month 60 visit. Among participants completing month 60, overall mean VALS improvement over baseline was 13.5 (95% CI: 9.6, 17.5), less than the mean improvement of 20.6 (95% CI: 18.7, 22.4) observed at month 12, with no significant differences between originally assigned study groups. Further, 66% (99/150) had at least 1 treatment between months 48 and 60 with a mean (SD) of 3.41 (3.69) treatments over this period. Mean CST was 671 μm at baseline and 261 μm (95% CI: 241.2, 280.9) at month 60. Although VALS improved substantially when patients were treated per protocol through month 12, improvement lessened when treatment was at investigator discretion and fewer treatments were received although VALS remained markedly improved over baseline through year 5. Most patients continued to receive treatment in year 5. This suggests that continued monitoring and, if warranted, treatment with anti-VEGF therapy benefits patients with macular edema associated with central retinal or hemiretinal vein occlusion. Publication of this article is sponsored by the American Ophthalmological Society.
AbstractList	PURPOSETo investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion.METHODSLong-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. Main outcomes were visual acuity letter score (VALS) and central subfield thickness (CST) on optical coherence tomography.RESULTSSeventy-five percent (248/330) of eligible participants completed at least 1 visit between months 24 and 60, and 45% completed the month 60 visit. Among participants completing month 60, overall mean VALS improvement over baseline was 13.5 (95% CI: 9.6, 17.5), less than the mean improvement of 20.6 (95% CI: 18.7, 22.4) observed at month 12, with no significant differences between originally assigned study groups. Further, 66% (99/150) had at least 1 treatment between months 48 and 60 with a mean (SD) of 3.41 (3.69) treatments over this period. Mean CST was 671 μm at baseline and 261 μm (95% CI: 241.2, 280.9) at month 60.CONCLUSIONSAlthough VALS improved substantially when patients were treated per protocol through month 12, improvement lessened when treatment was at investigator discretion and fewer treatments were received although VALS remained markedly improved over baseline through year 5. Most patients continued to receive treatment in year 5. This suggests that continued monitoring and, if warranted, treatment with anti-VEGF therapy benefits patients with macular edema associated with central retinal or hemiretinal vein occlusion. Publication of this article is sponsored by the American Ophthalmological Society. To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion. Long-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. Main outcomes were visual acuity letter score (VALS) and central subfield thickness (CST) on optical coherence tomography. Seventy-five percent (248/330) of eligible participants completed at least 1 visit between months 24 and 60, and 45% completed the month 60 visit. Among participants completing month 60, overall mean VALS improvement over baseline was 13.5 (95% CI: 9.6, 17.5), less than the mean improvement of 20.6 (95% CI: 18.7, 22.4) observed at month 12, with no significant differences between originally assigned study groups. Further, 66% (99/150) had at least 1 treatment between months 48 and 60 with a mean (SD) of 3.41 (3.69) treatments over this period. Mean CST was 671 μm at baseline and 261 μm (95% CI: 241.2, 280.9) at month 60. Although VALS improved substantially when patients were treated per protocol through month 12, improvement lessened when treatment was at investigator discretion and fewer treatments were received although VALS remained markedly improved over baseline through year 5. Most patients continued to receive treatment in year 5. This suggests that continued monitoring and, if warranted, treatment with anti-VEGF therapy benefits patients with macular edema associated with central retinal or hemiretinal vein occlusion. Publication of this article is sponsored by the American Ophthalmological Society. To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion.PURPOSETo investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion.Long-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. Main outcomes were visual acuity letter score (VALS) and central subfield thickness (CST) on optical coherence tomography.METHODSLong-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. Main outcomes were visual acuity letter score (VALS) and central subfield thickness (CST) on optical coherence tomography.Seventy-five percent (248/330) of eligible participants completed at least 1 visit between months 24 and 60, and 45% completed the month 60 visit. Among participants completing month 60, overall mean VALS improvement over baseline was 13.5 (95% CI: 9.6, 17.5), less than the mean improvement of 20.6 (95% CI: 18.7, 22.4) observed at month 12, with no significant differences between originally assigned study groups. Further, 66% (99/150) had at least 1 treatment between months 48 and 60 with a mean (SD) of 3.41 (3.69) treatments over this period. Mean CST was 671 μm at baseline and 261 μm (95% CI: 241.2, 280.9) at month 60.RESULTSSeventy-five percent (248/330) of eligible participants completed at least 1 visit between months 24 and 60, and 45% completed the month 60 visit. Among participants completing month 60, overall mean VALS improvement over baseline was 13.5 (95% CI: 9.6, 17.5), less than the mean improvement of 20.6 (95% CI: 18.7, 22.4) observed at month 12, with no significant differences between originally assigned study groups. Further, 66% (99/150) had at least 1 treatment between months 48 and 60 with a mean (SD) of 3.41 (3.69) treatments over this period. Mean CST was 671 μm at baseline and 261 μm (95% CI: 241.2, 280.9) at month 60.Although VALS improved substantially when patients were treated per protocol through month 12, improvement lessened when treatment was at investigator discretion and fewer treatments were received although VALS remained markedly improved over baseline through year 5. Most patients continued to receive treatment in year 5. This suggests that continued monitoring and, if warranted, treatment with anti-VEGF therapy benefits patients with macular edema associated with central retinal or hemiretinal vein occlusion. Publication of this article is sponsored by the American Ophthalmological Society.CONCLUSIONSAlthough VALS improved substantially when patients were treated per protocol through month 12, improvement lessened when treatment was at investigator discretion and fewer treatments were received although VALS remained markedly improved over baseline through year 5. Most patients continued to receive treatment in year 5. This suggests that continued monitoring and, if warranted, treatment with anti-VEGF therapy benefits patients with macular edema associated with central retinal or hemiretinal vein occlusion. Publication of this article is sponsored by the American Ophthalmological Society.
Author	Oden, Neal L. Ip, Michael S. Scott, Ingrid U. Blodi, Barbara A. VanVeldhuisen, Paul C.
Author_xml	– sequence: 1 givenname: Ingrid U. surname: Scott fullname: Scott, Ingrid U. email: iscott@pennstatehealth.psu.edu organization: From the Departments of Ophthalmology and Public Health Sciences (I.U.C.), Penn State College of Medicine, Hershey, Pennsylvania – sequence: 2 givenname: Paul C. surname: VanVeldhuisen fullname: VanVeldhuisen, Paul C. organization: The Emmes Company, LLC (P.C.V., N.L.O.), Rockville, Maryland – sequence: 3 givenname: Neal L. surname: Oden fullname: Oden, Neal L. organization: The Emmes Company, LLC (P.C.V., N.L.O.), Rockville, Maryland – sequence: 4 givenname: Michael S. surname: Ip fullname: Ip, Michael S. organization: Doheny Eye Institute (M.S.I.), University of California, Los Angeles, California – sequence: 5 givenname: Barbara A. surname: Blodi fullname: Blodi, Barbara A. organization: University of Wisconsin Fundus Photograph Reading Center (B.A.B.), Madison, Wisconsin, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35461831$$D View this record in MEDLINE/PubMed
BookMark	eNqFks9uEzEQxleoiKaFB-CCLHHhkmDv_xUHFIX-k1pFQlE5Wt7ZWeKwa6e2tyg33oG34LF4EiYkVJBDOY0t_77PM_rmJDoy1mAUvRR8IrjI364mamUnMY_jCU8nnIsn0UiURTUWZSWOohHnPB5XSZUeRyfer-iaF2nxLDpOsjQXZSJG0Y8ba8KS5ZzNhwC2R8-mbUDHFg5V6NEEdmV00Cpoa9gnTezUBP3z2_db5WHolGNnprFhiZ1WHbtw9ish5wqCJY8lOrXesJbON2pPN9gr9mFAFiybkb8j2UcM2lAl7hJ77fbXW9SGzQG6wdPvz6Onreo8vtjX02hxfraYXY6v5xdXs-n1GLKEh3ENRUGzxdCUaZNDVfO85hADb7GApkrKRuWVyFQLNWRxwdOmQaE4r3kR51gmp9H7ne16qHtsYNeiXDvdK7eRVmn574vRS_nZ3ksheJ7yrCKHN3sHZ-8G9EH22gN2nTJoBy_jPMuIpVwIfX2AruzgaPYtVYk0KeM0JurV3y099PInRgLEDgBnvXfYPiCCy-2qyJWkVZHbVZE8lbQqpCkONKDD75hpKt09qny3UyKlcK_RSQ8aDWBDyUGQjdWPqqsDNXTaaFDdF9z8R_sLuC3vHg
CitedBy_id	crossref_primary_10_1016_j_ajo_2022_12_026 crossref_primary_10_1016_j_oret_2025_05_025 crossref_primary_10_1038_s41433_023_02647_0 crossref_primary_10_1016_j_ophtha_2023_05_023 crossref_primary_10_1038_s41433_024_03008_1 crossref_primary_10_1016_j_ajo_2023_11_023 crossref_primary_10_1016_j_ajo_2024_04_027 crossref_primary_10_3390_vaccines10122143 crossref_primary_10_1136_bmjophth_2024_001659 crossref_primary_10_1016_j_ajo_2023_03_034 crossref_primary_10_1097_APO_0000000000000598 crossref_primary_10_1097_IAE_0000000000004157
Cites_doi	10.1016/j.ophtha.2011.12.005 10.1016/j.ajo.2014.07.027 10.1016/j.ophtha.2009.07.017 10.1016/j.ophtha.2010.03.032 10.1016/j.ophtha.2014.01.027 10.1016/0002-9394(84)90316-7 10.1016/j.ophtha.2008.10.017 10.1016/j.ophtha.2014.08.031 10.1016/j.ophtha.2015.09.035 10.1016/j.ophtha.2010.02.022 10.1016/j.ajo.2012.09.026 10.1001/jama.2013.281053 10.1016/S0161-6420(95)30849-4 10.1016/j.ophtha.2010.02.021 10.1016/S0161-6420(95)30848-2 10.1001/archopht.1996.01100140443012 10.1136/bjophthalmol-2012-301504 10.1001/archophthalmol.2009.233 10.1001/jamaophthalmol.2017.6843 10.1016/j.ophtha.2012.01.042 10.1001/archophthalmol.2009.234 10.1016/j.ophtha.2011.02.038 10.1016/j.ophtha.2013.08.038 10.1016/j.ophtha.2011.05.014 10.1001/archopht.1993.01090080083022 10.1186/s12874-018-0653-0 10.1001/jama.2017.4568 10.1001/jamaophthalmol.2019.3947
ContentType	Journal Article
Copyright	2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. 2022. Elsevier Inc.
Copyright_xml	– notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. – notice: 2022. Elsevier Inc.
CorporateAuthor	SCORE2 Investigator Group
CorporateAuthor_xml	– name: SCORE2 Investigator Group
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM
DOI	10.1016/j.ajo.2022.04.001
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic
DatabaseTitleList	ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1879-1891
EndPage	341
ExternalDocumentID	PMC11064059 35461831 10_1016_j_ajo_2022_04_001 S0002939422001441
Genre	Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NEI NIH HHS grantid: U10 EY023521 – fundername: NEI NIH HHS grantid: U10 EY023533 – fundername: NEI NIH HHS grantid: U10 EY023529
GroupedDBID	--- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AABNK AAEDT AAEDW AAHTB AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQX ABDPE ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPEJ ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACNCT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N4W N9A O-L O9- OAUVE OF- OPF OQ~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSZ SV3 T5K UNMZH UV1 VH1 WH7 WOW X7M XPP Z5R ZGI ZXP ~G- ~HD 3V. 7RV 7X7 8FI AACTN AAIAV ABLVK ABYKQ AFCTW AFKRA AFKWA AHPSJ AJBFU AJOXV AMFUW AZQEC BENPR FYUFA G8K GUQSH LCYCR M1P M2O RIG ZA5 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM
ID	FETCH-LOGICAL-c530t-bc771832cd84d6c9b06b0c2c0fe7cd938da6915afcbc52704dde1a00b0726e83
ISICitedReferencesCount	12
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000810517200013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0002-9394 1879-1891
IngestDate	Tue Sep 30 17:09:01 EDT 2025 Sun Sep 28 08:19:21 EDT 2025 Mon Oct 06 18:36:44 EDT 2025 Sat Nov 01 14:16:56 EDT 2025 Sat Nov 29 06:59:22 EST 2025 Tue Nov 18 21:46:29 EST 2025 Fri Feb 23 02:41:31 EST 2024 Tue Oct 14 19:35:28 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Language	English
License	Copyright © 2022 Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c530t-bc771832cd84d6c9b06b0c2c0fe7cd938da6915afcbc52704dde1a00b0726e83
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Author Contributions: Study concept and design: I.U.S., P.C.V., M.S.I., B.A.B., N.L.O.; Acquisition, analysis, or interpretation of data: I.U.S., P.C.V., M.S.I., B.A.B., N.L.O.; Drafting of the manuscript: I.U.S., N.L.O., P.C.V.; Critical revision of the manuscript for important intellectual content: M.S.I., B.A.B.; Statistical analysis: N.L.O.; Obtained funding: I.U.S., P.C.V., B.A.B.; Administrative, technical, or material support: P.C.V.; Study supervision: I.U.S., P.C.V., M.S.I., B.A.B.
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/11064059
PMID	35461831
PQID	2691438242
PQPubID	41749
PageCount	12
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_11064059 proquest_miscellaneous_2655106394 proquest_journals_2691438242 pubmed_primary_35461831 crossref_primary_10_1016_j_ajo_2022_04_001 crossref_citationtrail_10_1016_j_ajo_2022_04_001 elsevier_sciencedirect_doi_10_1016_j_ajo_2022_04_001 elsevier_clinicalkey_doi_10_1016_j_ajo_2022_04_001
PublicationCentury	2000
PublicationDate	2022-08-01
PublicationDateYYYYMMDD	2022-08-01
PublicationDate_xml	– month: 08 year: 2022 text: 2022-08-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Chicago
PublicationTitle	American journal of ophthalmology
PublicationTitleAlternate	Am J Ophthalmol
PublicationYear	2022
Publisher	Elsevier Inc Elsevier Limited
Publisher_xml	– name: Elsevier Inc – name: Elsevier Limited
References	Campochiaro, Clark, Boyer (bib0014) 2015; 122 (bib0004) 1993; 111 Clark, Boyer, Heier (bib0015) 2016; 123 Campochiaro, Heier, Feiner (bib0013) 2010; 117 Scott, Oden, VanVeldhuisen, Ip, Blodi, Chan (bib0026) 2019; 137 (bib0007) 1984; 98 (bib0006) 1997; 115 Boyer, Heier, Brown (bib0020) 2012; 119 Ogura, Roider, Korobelnik (bib0024) 2014; 158 De Silva, Moreno-Betancur, De Livera, Lee, Simpson (bib0028) 2019; 19 Campochiaro, Brown, Awh (bib0019) 2011; 118 Ip, Scott, VanVeldhuisen (bib0010) 2009; 127 Scott, VanVeldhuisen, Oden, Ip, Blodi, Jumper, Figueroa (bib0030) 2009; 116 Scott, Ip, VanVeldhuisen (bib0009) 2009; 127 (bib0005) 1995; 102 Brown, Campochiaro, Singh (bib0018) 2010; 117 Brown, Heier, Clark (bib0021) 2013; 155 Campochiaro, Sophie, Pearlman (bib0017) 2014; 121 Rogers, McIntosh, Cheung (bib0003) 2010; 117 Klein, Klein, Moss, Meuer (bib0002) 2000; 8 Heier, Clark, Boyer (bib0022) 2014; 121 Scott, VanVeldhuisen, Ip (bib0025) 2017; 317 Heier, Campochiaro, Yau (bib0016) 2012; 119 Scott, VanVeldhuisen, Ip (bib0029) 2018; 136 (bib0008) 1995; 102 Haller, Bandello, Belfort (bib0012) 2010; 117 Mitchell, Smith, Chang (bib0001) 1996; 114 (bib0027) 2013; 310 Haller, Bandello, Belfort (bib0011) 2011; 118 Holz, Roider, Ogura (bib0023) 2013; 97 Heier (10.1016/j.ajo.2022.04.001_bib0016) 2012; 119 Ogura (10.1016/j.ajo.2022.04.001_bib0024) 2014; 158 Campochiaro (10.1016/j.ajo.2022.04.001_bib0014) 2015; 122 Boyer (10.1016/j.ajo.2022.04.001_bib0020) 2012; 119 (10.1016/j.ajo.2022.04.001_bib0005) 1995; 102 Rogers (10.1016/j.ajo.2022.04.001_bib0003) 2010; 117 Heier (10.1016/j.ajo.2022.04.001_bib0022) 2014; 121 Scott (10.1016/j.ajo.2022.04.001_bib0009) 2009; 127 Haller (10.1016/j.ajo.2022.04.001_bib0012) 2010; 117 Scott (10.1016/j.ajo.2022.04.001_bib0029) 2018; 136 Haller (10.1016/j.ajo.2022.04.001_bib0011) 2011; 118 Campochiaro (10.1016/j.ajo.2022.04.001_bib0013) 2010; 117 (10.1016/j.ajo.2022.04.001_bib0027) 2013; 310 (10.1016/j.ajo.2022.04.001_bib0007) 1984; 98 Clark (10.1016/j.ajo.2022.04.001_bib0015) 2016; 123 Holz (10.1016/j.ajo.2022.04.001_bib0023) 2013; 97 (10.1016/j.ajo.2022.04.001_bib0004) 1993; 111 Brown (10.1016/j.ajo.2022.04.001_bib0018) 2010; 117 Campochiaro (10.1016/j.ajo.2022.04.001_bib0019) 2011; 118 (10.1016/j.ajo.2022.04.001_bib0006) 1997; 115 Scott (10.1016/j.ajo.2022.04.001_bib0025) 2017; 317 Campochiaro (10.1016/j.ajo.2022.04.001_bib0017) 2014; 121 (10.1016/j.ajo.2022.04.001_bib0008) 1995; 102 De Silva (10.1016/j.ajo.2022.04.001_bib0028) 2019; 19 Scott (10.1016/j.ajo.2022.04.001_bib0030) 2009; 116 Klein (10.1016/j.ajo.2022.04.001_bib0002) 2000; 8 Ip (10.1016/j.ajo.2022.04.001_bib0010) 2009; 127 Brown (10.1016/j.ajo.2022.04.001_bib0021) 2013; 155 Mitchell (10.1016/j.ajo.2022.04.001_bib0001) 1996; 114 Scott (10.1016/j.ajo.2022.04.001_bib0026) 2019; 137
References_xml	– volume: 122 start-page: 538 year: 2015 end-page: 544 ident: bib0014 article-title: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 24-week results of the VIBRANT study publication-title: Ophthalmology – volume: 102 start-page: 1425 year: 1995 end-page: 1433 ident: bib0008 article-title: Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. The Central Vein Occlusion Study Group M report publication-title: Ophthalmology – volume: 116 start-page: 504 year: 2009 end-page: 512 ident: bib0030 article-title: SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion publication-title: Ophthalmology – volume: 19 start-page: 14 year: 2019 ident: bib0028 article-title: Multiple imputation methods for handling missing values in a longitudinal categorical variable with restrictions on transitions over time: a simulation study publication-title: BMC Med Res Methodol – volume: 8 start-page: 133 year: 2000 end-page: 141 ident: bib0002 article-title: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study publication-title: Trans Am Ophthalmol Soc – volume: 317 start-page: 2072 year: 2017 end-page: 2087 ident: bib0025 article-title: Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion. The SCORE2 randomized clinical trial publication-title: JAMA – volume: 115 start-page: 486 year: 1997 end-page: 491 ident: bib0006 article-title: Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group publication-title: Arch Ophthalmol – volume: 119 start-page: 802 year: 2012 end-page: 809 ident: bib0016 article-title: Ranibizumab for macular edema due to retinal vein occlusions. Long-term follow-up in the HORIZON trial publication-title: Ophthalmology – volume: 136 start-page: 337 year: 2018 end-page: 345 ident: bib0029 article-title: Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications. Secondary outcomes from the SCORE2 randomized clinical trial publication-title: JAMA Ophthalmol – volume: 118 start-page: 2453 year: 2011 end-page: 2460 ident: bib0011 article-title: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results publication-title: Ophthalmology – volume: 119 start-page: 1024 year: 2012 end-page: 1032 ident: bib0020 article-title: Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS Study publication-title: Ophthalmology – volume: 114 start-page: 1243 year: 1996 end-page: 1247 ident: bib0001 article-title: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study publication-title: Arch Ophthalmol – volume: 117 start-page: 1134 year: 2010 end-page: 1146 ident: bib0012 article-title: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion publication-title: Ophthalmology – volume: 137 start-page: 1389 year: 2019 end-page: 1398 ident: bib0026 article-title: Month 24 outcomes after treatment initiation with anti-vascular endothelial growth factor therapy for macular edema due to central retinal or hemiretinal vein occlusion. SCORE2 report 10: a secondary analysis of the SCORE2 randomized clinical trial publication-title: JAMA Ophthalmol – volume: 127 start-page: 1115 year: 2009 end-page: 1128 ident: bib0009 article-title: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6 publication-title: Arch Ophthalmol – volume: 127 start-page: 1101 year: 2009 end-page: 1114 ident: bib0010 article-title: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 publication-title: Arch Ophthalmol – volume: 117 start-page: 1102 year: 2010 end-page: 1112 ident: bib0013 article-title: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study publication-title: Ophthalmology – volume: 111 start-page: 1087 year: 1993 end-page: 1095 ident: bib0004 article-title: Baseline and early natural history report. The Central Vein Occlusion Study publication-title: Arch Ophthalmol – volume: 117 start-page: 1124 year: 2010 end-page: 1133 ident: bib0018 article-title: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point of a phase III study publication-title: Ophthalmology – volume: 155 start-page: 429 year: 2013 end-page: 437 ident: bib0021 article-title: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study publication-title: Am J Ophthalmol – volume: 121 start-page: 209 year: 2014 end-page: 219 ident: bib0017 article-title: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN study publication-title: Ophthalmology – volume: 102 start-page: 1434 year: 1995 end-page: 1444 ident: bib0005 article-title: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report publication-title: Ophthalmology – volume: 158 start-page: 1032 year: 2014 end-page: 1038 ident: bib0024 article-title: Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study publication-title: Am J Ophthalmol – volume: 97 start-page: 278 year: 2013 end-page: 284 ident: bib0023 article-title: VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study publication-title: Br J Ophthalmol – volume: 117 start-page: 313 year: 2010 end-page: 319 ident: bib0003 article-title: the International Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia publication-title: Ophthalmology – volume: 310 start-page: 2191 year: 2013 end-page: 2194 ident: bib0027 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: JAMA – volume: 118 start-page: 2041 year: 2011 end-page: 2049 ident: bib0019 article-title: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study publication-title: Ophthalmology – volume: 121 start-page: 1414 year: 2014 end-page: 1420 ident: bib0022 article-title: Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results from the COPERNICUS study publication-title: Ophthalmology – volume: 98 start-page: 271 year: 1984 end-page: 282 ident: bib0007 article-title: Argon laser photocoagulation for macular edema in branch vein occlusion publication-title: Am J Ophthalmol – volume: 123 start-page: 330 year: 2016 end-page: 336 ident: bib0015 article-title: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study publication-title: Ophthalmology – volume: 119 start-page: 802 issue: 4 year: 2012 ident: 10.1016/j.ajo.2022.04.001_bib0016 article-title: Ranibizumab for macular edema due to retinal vein occlusions. Long-term follow-up in the HORIZON trial publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.12.005 – volume: 158 start-page: 1032 issue: 5 year: 2014 ident: 10.1016/j.ajo.2022.04.001_bib0024 article-title: Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.07.027 – volume: 8 start-page: 133 year: 2000 ident: 10.1016/j.ajo.2022.04.001_bib0002 article-title: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study publication-title: Trans Am Ophthalmol Soc – volume: 117 start-page: 313 issue: 2 year: 2010 ident: 10.1016/j.ajo.2022.04.001_bib0003 article-title: the International Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.07.017 – volume: 117 start-page: 1134 issue: 6 year: 2010 ident: 10.1016/j.ajo.2022.04.001_bib0012 article-title: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.03.032 – volume: 121 start-page: 1414 issue: 7 year: 2014 ident: 10.1016/j.ajo.2022.04.001_bib0022 article-title: Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results from the COPERNICUS study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.01.027 – volume: 98 start-page: 271 issue: 3 year: 1984 ident: 10.1016/j.ajo.2022.04.001_bib0007 article-title: Argon laser photocoagulation for macular edema in branch vein occlusion publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(84)90316-7 – volume: 116 start-page: 504 issue: 3 year: 2009 ident: 10.1016/j.ajo.2022.04.001_bib0030 article-title: SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.10.017 – volume: 122 start-page: 538 issue: 3 year: 2015 ident: 10.1016/j.ajo.2022.04.001_bib0014 article-title: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 24-week results of the VIBRANT study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.08.031 – volume: 123 start-page: 330 issue: 2 year: 2016 ident: 10.1016/j.ajo.2022.04.001_bib0015 article-title: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2015.09.035 – volume: 117 start-page: 1124 issue: 6 year: 2010 ident: 10.1016/j.ajo.2022.04.001_bib0018 article-title: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point of a phase III study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.02.022 – volume: 155 start-page: 429 issue: 3 year: 2013 ident: 10.1016/j.ajo.2022.04.001_bib0021 article-title: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2012.09.026 – volume: 310 start-page: 2191 issue: 20 year: 2013 ident: 10.1016/j.ajo.2022.04.001_bib0027 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: JAMA doi: 10.1001/jama.2013.281053 – volume: 102 start-page: 1425 issue: 10 year: 1995 ident: 10.1016/j.ajo.2022.04.001_bib0008 article-title: Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. The Central Vein Occlusion Study Group M report publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)30849-4 – volume: 115 start-page: 486 issue: 10 year: 1997 ident: 10.1016/j.ajo.2022.04.001_bib0006 article-title: Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group publication-title: Arch Ophthalmol – volume: 117 start-page: 1102 issue: 6 year: 2010 ident: 10.1016/j.ajo.2022.04.001_bib0013 article-title: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.02.021 – volume: 102 start-page: 1434 issue: 10 year: 1995 ident: 10.1016/j.ajo.2022.04.001_bib0005 article-title: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)30848-2 – volume: 114 start-page: 1243 issue: 10 year: 1996 ident: 10.1016/j.ajo.2022.04.001_bib0001 article-title: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study publication-title: Arch Ophthalmol doi: 10.1001/archopht.1996.01100140443012 – volume: 97 start-page: 278 issue: 3 year: 2013 ident: 10.1016/j.ajo.2022.04.001_bib0023 article-title: VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2012-301504 – volume: 127 start-page: 1115 issue: 9 year: 2009 ident: 10.1016/j.ajo.2022.04.001_bib0009 publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2009.233 – volume: 136 start-page: 337 issue: 4 year: 2018 ident: 10.1016/j.ajo.2022.04.001_bib0029 article-title: Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications. Secondary outcomes from the SCORE2 randomized clinical trial publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2017.6843 – volume: 119 start-page: 1024 issue: 5 year: 2012 ident: 10.1016/j.ajo.2022.04.001_bib0020 article-title: Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS Study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.01.042 – volume: 127 start-page: 1101 issue: 9 year: 2009 ident: 10.1016/j.ajo.2022.04.001_bib0010 publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2009.234 – volume: 118 start-page: 2041 issue: 10 year: 2011 ident: 10.1016/j.ajo.2022.04.001_bib0019 article-title: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.02.038 – volume: 121 start-page: 209 issue: 1 year: 2014 ident: 10.1016/j.ajo.2022.04.001_bib0017 article-title: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.08.038 – volume: 118 start-page: 2453 issue: 12 year: 2011 ident: 10.1016/j.ajo.2022.04.001_bib0011 article-title: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.05.014 – volume: 111 start-page: 1087 issue: 8 year: 1993 ident: 10.1016/j.ajo.2022.04.001_bib0004 article-title: Baseline and early natural history report. The Central Vein Occlusion Study publication-title: Arch Ophthalmol doi: 10.1001/archopht.1993.01090080083022 – volume: 19 start-page: 14 issue: 1 year: 2019 ident: 10.1016/j.ajo.2022.04.001_bib0028 article-title: Multiple imputation methods for handling missing values in a longitudinal categorical variable with restrictions on transitions over time: a simulation study publication-title: BMC Med Res Methodol doi: 10.1186/s12874-018-0653-0 – volume: 317 start-page: 2072 issue: 20 year: 2017 ident: 10.1016/j.ajo.2022.04.001_bib0025 article-title: Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion. The SCORE2 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.4568 – volume: 137 start-page: 1389 issue: 12 year: 2019 ident: 10.1016/j.ajo.2022.04.001_bib0026 article-title: Month 24 outcomes after treatment initiation with anti-vascular endothelial growth factor therapy for macular edema due to central retinal or hemiretinal vein occlusion. SCORE2 report 10: a secondary analysis of the SCORE2 randomized clinical trial publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2019.3947
SSID	ssj0006747
Score	2.452527
Snippet	To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein... PURPOSETo investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein...
SourceID	pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	330
SubjectTerms	Angiogenesis Inhibitors Bevacizumab - therapeutic use Diabetes Diabetic retinopathy Edema FDA approval Humans Intravitreal Injections Lasers Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Medical records Monoclonal antibodies Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins Retinal Vein Occlusion - complications Retinal Vein Occlusion - diagnosis Retinal Vein Occlusion - drug therapy Tomography, Optical Coherence Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors
Title	Month 60 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0002939422001441 https://dx.doi.org/10.1016/j.ajo.2022.04.001 https://www.ncbi.nlm.nih.gov/pubmed/35461831 https://www.proquest.com/docview/2691438242 https://www.proquest.com/docview/2655106394 https://pubmed.ncbi.nlm.nih.gov/PMC11064059
Volume	240
WOSCitedRecordID	wos000810517200013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-1891 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006747 issn: 0002-9394 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9owFLVoO017mfY9tq7ypGkPQ6lMPuzkEW2wMrUwaZTxFjmOGaloYBCq_qT9n_2hXTt2gHbruoe9IEjsBLgn177Xx-ci9AYmqUrlizsylJ7jc_CDieunTsAElVwrgHFdbIL1euFoFH2u1X7avTAXU5bn4eVlNP-vpoZjYGy1dfYfzF1dFA7AezA6vILZ4fVWhoentJg0KGn0VwVcXy4bLV0HfFBRyruKMFQa_qtKw7byInOGlpLazlO1K2uqUukfIUiHBh1dlEexM5QCgWYmnnDTOpXnvPFhpStwmFQx2KzQxbag3ZE8zxbm41BmuZI1nq6WFg1W_9auG20IWczmk2LCp-dbef8vwhBMuvm3RZY2Tu2JIc-HcppOVplJKSnK4zoF3Dfutad0lKt8d3e-sXPAJIFNBgSCZ8u_s047ZJHTDMuqX4fyN8eMp3dLZSjjq71yQejaGFKmM84O-ZnaHOq6WgrX3G9Lr7vXjzunx8fxoD0avJ1_d1QpM7Xkb-q67KA9lwURuNq9Vrc9-lRNECjTde-qr2gX2zXt8Mpd_zRduh4OXWX1bkyTBg_QfRPf4FaJy4eoJvNH6O6JYXA8Rj80PDEl2MITa3jiCp54DU-s4Im34Ik34IlLeOISntjAEwM8sYEn1vDEAE9czLCBJzbwxNBuA55YwRNX8HyCBp324P2RY6qFOCLwSOEkgjE1Pok09FMqooTQhAhXkLFkIo28MOU0agZ8LBIRuIz4MLA3OSEJYS6VofcU7eazXD5HmHpJQiWVfpOM_THEdTJMIhlSLsbjgDJRR8TaJBZGSV8VdJnGljJ5FoMZY2XGmPiKNlpH76ou81JG5qbGrjV0bPdHw4geA0Bv6uRXnczkuZwU_63bvkVSbB7xZezCH6UIAr5bR6-r0zDuqMVEnsvZSrWBWEvFN34dPSuBV_0yL_ApmAIuHm5BsmqgNO23z-TZRGvbQzRCIYaMXtzixi_RvbU72Ee7xWIlX6E74qLIlosDtMNG4YF59n4BOx0ddQ
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Month+60+Outcomes+After+Treatment+Initiation+With+Anti-Vascular+Endothelial+Growth+Factor+Therapy+for+Macular+Edema+Due+to+Central+Retinal+or+Hemiretinal+Vein+Occlusion&rft.jtitle=American+journal+of+ophthalmology&rft.au=Scott%2C+Ingrid+U&rft.au=VanVeldhuisen%2C+Paul+C&rft.au=Oden%2C+Neal+L&rft.au=Ip%2C+Michael+S&rft.date=2022-08-01&rft.issn=1879-1891&rft.eissn=1879-1891&rft.volume=240&rft.spage=330&rft_id=info:doi/10.1016%2Fj.ajo.2022.04.001&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9394&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9394&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9394&client=summon